18F-FDG PET/CT for the assessment of myocardial sarcoidosis

Current Cardiology Reports

Volumn 15, Issue 4, 2013, Pages

  Skali, Hicham ^a,b   Schulman, Allison R ^c   Dorbala, Sharmila ^a,b  

^a Department of Radiology Division of Nuclear Medicine and Molecular imaging   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiac sarcoidosis; Myocardial sarcoidosis; PET

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; PREDNISONE;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ACTIVITY; EARLY DIAGNOSIS; HUMAN; MONITORING; MYOCARDIAL PERFUSION IMAGING; MYOCARDITIS; PATHOPHYSIOLOGY; PROGNOSIS; SARCOIDOSIS; TREATMENT RESPONSE;

EID: 84895074400     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0370-6     Document Type: Article

References (48)

1. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-11. (Pubitemid 9092005)
2. Nomura S, Funabashi N, Tsubura M, Uehara M, Shiina Y, Daimon M, et al. Cardiac sarcoidosis evaluated by multimodality imaging. Int J Cardiol. 2011;150:e81-4.
3. Kim JS, JudsonMA, Donnino R, GoldM, Cooper Jr LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21.
4. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253-8. (Pubitemid 23027268)
5. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078-87.
6. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-8.
7. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455-69.
8. Hiraga H, Hiroe M, Iwai K, et al. Guideline for the diagnosis of cardiac sarcoidosis: study report on Diffuse Pulmonary Diseases (in Japanese). 1993:23-4.
9. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3:1219-28.
10. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis and Granulomatous Disorders (in Japanese). 2007;27:89-102.
11. Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86-108. (Pubitemid 8146656)
12. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2 Pt 1):299-302. (Pubitemid 29379681)
13. Ratner SJ, Fenoglio Jr JJ, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest. 1986;90:528-33. (Pubitemid 17191564)
14. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030-6. (Pubitemid 39663376)
15. Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation. 2002;105:1144-5. (Pubitemid 34212627)
16. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153-65.
17. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282-8. (Pubitemid 43131983)
18. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010;51:1937-49.
19. Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, et al. Comparative evaluation of 18F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571-6. (Pubitemid 47545019)
20. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538-43. (Pubitemid 41373496)
21. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989-98. (Pubitemid 47611626)
22. Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J. 2007;29:418-22. (Pubitemid 46231921)
23. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426-35. (Pubitemid 351893001)
24. Newsholme P, Newsholme EA. Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem J. 1989;261:211-8. (Pubitemid 19174780)
25. Isiguzo M, Brunken R, Tchou P, Xu M, Culver DA. Metabolismperfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:50-5.
26. Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:87-94.
27. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801-10.
28. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563-8.
29. Williams G, Kolodny GM. Suppression of myocardial 18FFDG uptake by preparing patients with a high-fat, lowcarbohydrate diet. Am J Roentgenol. 2008;190:W151-6.
30. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926-36.
31. Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol. 2002;4:232-7. (Pubitemid 34705226)
32. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Gropler RJ, et al. PET Myocardial Perfusion and Metabolism Clinical Imaging. J Nucl Cardiol 2009;16. doi:10.1007/s12350-009-9094-9. Available at: http://www.asnc.org/imageuploads/ImagingGuidelinesPETJuly2009.pdf. Accessed 24 Jan 2013.
33. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo, et al. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941-73.
34. Blankstein R, Naya M, Osborne M, Kim C, Murthy V, Kwong R, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoid. J Am Coll Cardiol. 2011;59:E1310.
35. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012;125:76-86.
36. Pierre-Louis B, Prasad A, Frishman WH. Cardiac manifestations of sarcoidosis and therapeutic options. Cardiol Rev. 2009;17:153-8.
37. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20:578-83.
38. Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143-6. (Pubitemid 40051133)
39. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-10. (Pubitemid 33042612)
40. Mantini N, Williams Jr B, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: a clinician's review on how to approach the patient with cardiac sarcoid. Clin Cardiol. 2012;35:410-5.
41. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933-41.
42. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97:173-82. (Pubitemid 39286832)
43. Matthews R, Bench T, Meng H, FranceschiD, Relan N, Brown DL. Diagnosis and monitoring of cardiac sarcoidosis with delayedenhanced MRI and 18F-FDG PET-CT. J Nucl Cardiol. 2012;19:807-10.
44. Yazaki Y, Isobe M, Hayasaka M, Tanaka M, Fujii T, Sekiguchi M. Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J. 1998;62:465-8.
45. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Hear Rhythm. 2012;9:884-91.
46. Haraki T, Ueda K, Shintani H, Hayashi T, Taki J, Mabuchi H. Spontaneous development of left ventricular aneurysm in a patient with untreated cardiac sarcoidosis. Circ J. 2002;66:519-21.
47. Deng JC, Baughman RP, Lynch III JP. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med. 2002;23:513-27. (Pubitemid 36026365)
48. Ohira H, Tsujino I, Yoshinaga K. (1)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773-83.